相关实验视频

Updated: May 31, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

奥里多宁通过向S100A1111抑制肺癌恶性进展

Yulin Luo^1,2, Jingjing Li^1,2, Yao Chen²

¹Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P.R. China.

Current medicinal chemistry

|January 24, 2025

概括

一种天然化合物奥里多宁有效抑制肺癌 (LC) 细胞生长和转移. 这项研究揭示了奥里多宁向S100A11,为治疗这种致命癌症提供了潜在的新策略.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

肺癌 (LC) 是癌症死亡的主要原因,有效治疗方法有限.
癌症的致病机制需要进一步阐明.
来自Rabdosia rubescens的奥里多宁显示出抗癌潜力,但其在LC中的作用尚未被探索.

研究的目的:

为了研究奥里多宁素对肺癌进展的影响.
阐明奥里多宁在LC中的作用的潜在分子机制.
在LC治疗中确定奥里多宁的潜在治疗点.

主要方法:

细胞增殖和迁移测试 (CCK8,EDU,Transwell,伤口愈合) 在用丁治疗的A549和Hcc1833细胞上进行.
在体内模型 (皮下瘤,尾静脉转移) 评估了奥里多宁对瘤生长和转移的疗效.
蛋白质组学,LiP-SMap,微尺度热泳和分子对接确定了奥里多宁与S100A11的相互作用.

主要成果:

奥里多宁剂量依赖地抑制了肺癌细胞的增殖和迁移.
在体内研究证实了奥里多宁抑制瘤生长和转移.
奥里多宁直接与S100A11的Asn-53残留物相互作用,抑制其激活;S100A11的过度表达抵消了奥里多宁的作用.

结论:

奥里多宁表现出显著的抗肺癌活性.
这项研究确定S100A11是肺癌中奥里多宁的关键分子标.
用奥里多宁向S100A11为肺癌提供了一个有前途的治疗策略.

关键词:

它们是有机的或无机的.在S100A11.11中,使用的是S100A11.肺癌是一种肺癌.恶性进展的恶性进展.

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...